Delivery Order SPE2DB22D1106-SPE2DB25FEWF4
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,594.16 Firm Fixed Price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract is not set aside and has a period of performance ending on July 14, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,188.32 delivery order contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract is a firm fixed price award with an ultimate completion date of August 7, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Delivery Order with a firm fixed price of $3,188.32 and an ultimate completion date of August 1, 2025. The contract is for the provision of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
- This is a federal contract award by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a firm fixed price ceiling value of $4,782.48 and a completion date of July 2, 2025. The contract is a delivery order and does not have a set-aside designation, indicating open competition....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medication, with a ceiling value of $1,594.16 and a period of performance through July 24, 2025. The contract is not set aside and was awarded on July 2, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,688.08 firm fixed price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product. The contract has a period of performance through May 28, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medical supplies. The $9,564.96 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 7, 2025. The contract is not designated as a set-aside and was competitively awarded. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a ceiling value of $3,188.32. The contract is a Firm Fixed Price Delivery Order, with a period of performance running through July 31, 2025. The award is not designated as a set-aside contract, indicating open...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medical products. The award has a ceiling value of $15,941.60 and a completion date of July 3, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor for this award, which is associated with...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a ceiling value of $6,376.64. The contract has a firm fixed price pricing type and an ultimate completion date of July 23, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEWF4Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,782.48 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a performance period ending on July 24, 2025. The contract is not set aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a comprehensive global pharmaceutical support vehicle, enabling Amerisourcebergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The IDC has a performance period extending through December 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 7/2/25 |